Tumor Chemosensitivity Assays

Number: 0245

Table Of Contents

Policy
Applicable CPT / HCPCS / ICD-10 Codes
Background
References

---

Policy

Scope of Policy

This Clinical Policy Bulletin addresses tumor chemosensitivity assays.

1. Experimental, Investigational, or Unproven

   Aetna considers chemosensitivity assays (e.g., the ChemoFx assay, the differential staining cytotoxicity (DiSC) assay, the fluorescence (Cytoprint) assay, the human tumor cloning assay (HTCA), the human tumor stem cell assay, the methyl thiazolyl-diphenyl-tetrazolium bromide (MTT) assay, and the microculture kinetic (MiCK) apoptosis assay (also known as CorrectChemo)) experimental, investigational, or unproven because there is insufficient evidence that these assays influence management decisions such that clinical outcomes are improved.

   Aetna considers the NexGen Cancer Cytotoxicity Assay, the 3D Predict Glioma (Kiyatec Inc.), and Reverse Phase Protein Array (Theralink) experimental, investigational, or unproven because there is a lack of reliable evidence that they alter management such that clinical outcomes are improved.

   Aetna considers cancer stem cell chemotherapeutic drug cytotoxicity assays (e.g., ChemoID, ChemoID Lab, and Cordgenics, LLC) experimental, investigational, or unproven because there is insufficient evidence that these assays influence management decisions such that clinical outcomes are improved.

2. Related Policies

   • CPB 0758 - Tumor Chemoresistance Assays

---

Table:

CPT Codes / HCPCS Codes / ICD-10 Codes

Code	Code Description
CPT codes not covered for indications listed in the CPB:
Differential staining cytotoxicity (DiSC) assay, Human tumor cloning assay (HTCA), Human tumor stem cell assay, Methyl thiazolyl-diphenyl-tetrazolium bromide (MTT) assay, Microculture kinetic (MiCK) apoptosis assay (CorrectChemo), Cytoprint assay - no specific code
0248U	Oncology (brain), spheroid cell culture in a 3D microenvironment, 12 drug panel, tumor-response prediction for each drug
0249U	Oncology (breast), semiquantitative analysis of 32 phosphoproteins and protein analytes, includes laser capture microdissection, with algorithmic analysis and interpretative report
0435U	Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on cytotoxicity percentage observed, minimum of 14 drugs or drug combinations
0564T	Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on percent of cytotoxicity observed, a minimum of 14 drugs or drug combinations
81535	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; first single drug or drug combination [ChemoFX assay]
81536	each additional single drug or drug combination (List separately in addition to code for primary procedure) [ChemoFX assay]
87230	Toxin or antitoxin assay, tissue culture (e.g., Clostridium difficile toxin)
88104	Cytopathology, fluids, washings or brushing, except cervical or vaginal; smears with interpretation
88305	Level IV surgical pathology, gross and microscopic examination
88313	Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry
88358	Morphometric analysis; tumor (e.g., DNA ploidy)
89050	Cell count, miscellaneous body fluids (e.g., cerebrospinal fluid, joint fluid), except blood
Other CPT codes related to the CPB:
88230	Tissue culture for non-neoplastic disorders; lymphocyte
88233	skin or other solid tissue biopsy
88235	amniotic fluid or chorionic villus cells
88237	Tissue culture for neoplastic disorders; bone marrow, blood cells
88239	solid tumor
Other HCPCS codes related to the CPB:
J9000 - J9999	Chemotherapy drugs
ICD-10 codes not covered for indications listed in the CPB:
C00.0 - D49.9	Neoplasms

---

Background

Chemosensitivity assays are intended to predict the sensitivity of various tumors to chemotherapeutic agents, with the intent of identifying more effective treatment protocols which would then translate into improved clinical survival.  By contrast, tumor chemoresistance assays are focused on identifying resistant drugs.  The focus of this policy is on tumor chemosensitivity assays.

1. isolation of cells;
2. incubation of cells with drugs;
3. assessment of cell survival; and
4. interpretation of the result.

There have been no prospective clinical trials that have demonstrated that there is an improved survival among patients in whom chemosensitivity assays were used to positively select chemotherapy regimens.

Although numerous attempts have been made to analyze the effects of drugs on cell metabolism, cell morphology, radionuclide incorporation, and various aspects of cell membrane integrity, there is no consensus that these assays can be utilized routinely in the clinical setting.  Major questions remain unanswered, such as how best to select patients who benefit from these tests and whether patients receiving assay-selected chemotherapy show better response than those receiving best current therapy.

Based on a review of the current literature, the American Society of Clinical Oncology (ASCO) Working Group found insufficient evidence to support the use of any chemotherapy sensitivity and resistance assays (CSRAs) in oncological practice.  Specifically, the ASCO Work Group found limitations in the literature that included small sample sizes and a lack of prospective studies.  For technically challenging CSRAs that require colony formation (e.g., the human tumor cloning assay), and for surgical procedures including the sub-renal capsule assay, the success rate of the CSRAs is modest.  Furthermore, preparation of the assay may involve complex laboratory work, limiting a broad application of the technology to routine clinical practice.  Because the in-vitro analytic strategy has potential importance, participation in clinical trials evaluating these technologies remains a priority (Schrag et al, 2004).

In a prospective, randomized controlled study, Cree and colleagues (2007) ascertained response rate and progression-free survival (PFS) following chemotherapy in patients with platinum-resistant recurrent ovarian cancer, who had been treated according to an adenosine triphosphate (ATP) bioluminescence-based tumor chemosensitivity assay in comparison with physician's choice.  A total of 180 patients were randomized to assay-directed therapy (n = 94) or physician's-choice chemotherapy (n = 86).  Median follow-up at analysis was 18 months.  Response was assessable in 147 patients: 31.5 % achieved a partial or complete response in the physician's-choice group compared with 40.5 % in the assay-directed group (26 versus 31 % by intention-to-treat analysis respectively).  Intention-to-treat analysis showed a median PFS of 93 days in the physician's-choice group and 104 days in the assay-directed group (hazard ratio [HR] 0.8, 95 % confidence interval [CI]: 0.59 to 1.10, not significant).  No difference was seen in overall survival (OS) between the groups, although 12/39 (41 %) of patients who crossed-over from the physician's-choice arm obtained a response.  Increased use of combination therapy was seen in the physician's-choice arm during the study as a result of the observed effects of assay-directed therapy in patients.  Patients entering the physician's-choice arm of the study during the first year did significantly worse than those who entered in the subsequent years (HR 0.44, 95 % CI: 0.2  to 0.9, p < 0.03).  The authors concluded that the findings of this small randomized clinical trial has documented a trend towards improved response and PFS for assay-directed treatment.  Chemosensitivity testing might provide useful information in some patients with ovarian cancer, although a larger trial is required to confirm this.  They noted that the ATP-based tumor chemosensitivity assay remains an investigational method in this condition.

In a systematic review and meta-analysis on the use of microsatellite instability (MSI) in predicting the effectiveness of chemotherapy in metastatic colorectal cancer (CRC), Des Guetz et al (2009) stated that MSI status is a good prognostic factor for CRC; but its predictive value for chemosensitivity remains controversial.  Studies were identified by electronic search through PubMed, Embase and ASCO proceedings online databases, using several key words (colorectal cancer, chemotherapy, microsatellite instability).  For each study, the ratio of response rate (RR), complete response (CR) and partial response (PR) divided by stable disease and progression was calculated.  From a total of 190 articles and 100 abstracts, only 8 independent studies were selected.  The data were analysed with a random-effect model (due to heterogeneity between studies) using EasyMA software.  Statistical calculations were performed on 6 studies representing 964 patients (mean age of 63 years; 91 MSI-high; 873 microsatellite stable (MSS) tumors).  A total of 287 patients received 5-fluorouracil (5FU)-based chemotherapy, whereas 678 patients received combinations of 5FU or capecitabine with oxaliplatin and/or irinotecan.  No benefit of metastatic chemotherapy in terms of RR for MSI-high patients compared with MSS patients was found.  The global HR for RR was 0.82 (95 % CI: 0.65 to 1.03; p = 0.09).  The authors concluded that MSI status does not predict the effect of chemotherapy, which is similar in MSI-high and MSS metastatic CRC tumors.

Kim and colleagues (2010) determined the most accurate analytic method to define in vitro chemosensitivity, using clinical response as reference standard in prospective clinical trial, and ascertained accuracy of adenosine triphosphate-based chemotherapy response assay (ATP-CRA).  A total of 48 patients with chemo-naïve, histologically confirmed, locally advanced or metastatic gastric cancer were enrolled for the study and were treated with combination chemotherapy of paclitaxel 175 mg/m(2) and cisplatin 75 mg/m(2) for maximum of 6 cycles after obtaining specimen for ATP-CRA.  These researchers performed the receiver operator characteristic (ROC) curve analysis using patient responses by World Health Organization criteria and ATP-CRA results to define the method with the highest accuracy.  Median PFS was 4.2 months (95 % CI: 3.4 to 5.0) and median OS was 11.8 months (95 % CI: 9.7 to 13.8) for all enrolled patients.  Chemosensitivity index method yielded highest accuracy of 77.8 % by ROC curve analysis, and the specificity, sensitivity, positive and negative predictive values were 95.7 %, 46.2 %, 85.7 %, and 75.9 %, respectively.  In-vitro chemosensitive group showed higher response rate (85.7 % versus 24.1 %) (p = 0.005) compared to chemoresistant group.  The authors concluded that ATP-CRA could predict clinical response to paclitaxel and cisplatin chemotherapy with high accuracy in advanced gastric cancer patients.  They stated that these findings support the use of ATP-CRA in further validation studies.

Schink and Copeland (2011) stated that in this era of personalized medicine, patients with recurrent ovarian cancer deserve better than the 25 % response rate that is associated with drugs selected based on clinical information alone.  In the past decade, marked laboratory improvements have enabled chemosensitivity assay testing to yield a 0.70 correlation with response, and to accurately predict PFS and OS.  Compelling retrospective data supporting the use of this technology can not be ignored while waiting for a co-operative group to test whether chemosensitivity assay should be used to direct salvage therapy.  In contrast, Markman (2011) stated that unfortunately, no reliable evidence-based data have shown any in-vitro chemosensitivity assay strategy to be clinically useful in the management of recurrent ovarian cancer, despite frequent use.  Several clinical trials have been proposed with the potential to support or refute the relevance of these approaches.

Huh et al (2011) examined the patterns of in-vitro tumor response rates as determined by ChemoFx are consistent with expected population response rates.  A total of 923 tumor specimens from patients with high-risk early-stage, advanced stage, or recurrent endometrial cancer were sent for testing with the ChemoFx drug response marker from August 2, 2006, to August 31, 2009.  Tumors were categorized as responsive (R), intermediately responsive (IR), or non-responsive (NR) to each drug or combination tested.  Response rates from clinical trials were identified and compared with the corresponding in vitro response rates.  Of the 923 specimens received, 759 (82 %) were successfully tested by ChemoFx.  Of these, 755 were tested for at least 1 of 5 National Comprehensive Cancer Network-recommended endometrial cancer drugs.  The response rates (R+IR) for these drugs were as follows: 66 % carboplatin-paclitaxel, 48 % carboplatin, 37 % cisplatin, 23 % doxorubicin, and 36 % paclitaxel.  Moreover, 20 % of tumors were pan-sensitive (R or IR) to all 5 regimens tested, 27 % were pan-resistant (NR), and 53 % showed different degrees of response to different drugs.  The authors concluded that ChemoFx in-vitro response rates were consistent with published population response rates, and the ChemoFx drug response marker may provide clinically useful information to better optimize individual chemotherapy for treatment of women with endometrial cancer.

Burstein et al (2011) updated the ASCO Technology Assessment guidelines on CSRAs published in 2004.  An Update Working Group reviewed data published between December 1, 2003, and May 31, 2010.  Medline and the Cochrane Library were searched yielding 11,313 new articles.  The limits for "human and English" were used, and then standard ASCO search strings for randomized controlled trials (RCTs), meta-analyses, guidelines, and reviews were added, yielding 1,298 articles for abstract review.  Of these, only 21 articles met pre-defined inclusion criteria and underwent full text review, and 5 reports of RCTs were included for data extraction.  Review of the literature does not identify any CSRAs for which the evidence base is sufficient to support use in oncology practice.  The authors concluded that the use of CSRAs to select chemotherapeutic agents for individual patients is not recommended outside of the clinical trial setting.  They noted that oncologists should make chemotherapy treatment recommendations based on published reports of clinical trials and a patient's health status and treatment preferences.  Because the in vitro analytic strategy has potential importance, participation in clinical trials evaluating these technologies remains a priority.

The in-vitro microculture kinetic (MiCK) assay, a drug-induced apoptosis assay, has been used to predict single or combination chemotherapy response in leukemia patients.  In the MiCK apoptosis assay, the extent of apoptosis is reported in kinetic units (KU), which are determined by the slope of the curve created when optical density caused by cell blebbing is plotted as a function of time (Kravtsov et al, 1998). 

In a feasibility study, Ballard et al (2010) examined the use of the MiCK apoptosis assay in endometrial cancer specimens.  Endometrial cancer specimens from total abdominal hysterectomies were processed at a central laboratory.  Single cell suspensions of viable endometrial cancer cells were plated in individual wells.  Single and combination regimens were tested: combinations of doxorubicin, cisplatin, and paclitaxel and carboplatin and paclitaxel (Gynecologic Oncology Group [GOG] 209 endometrial cancer phase III trial arms) as well as single-agent testing with paclitaxel, carboplatin, doxorubicin, cisplatin, ifosfamide, and vincristine (active agents in GOG trials).  Apoptosis was measured continuously over 48 hours.  Fifteen of 19 patients had successful assays.  The highest mean chemo sensitivity was noted in the combination of cisplatin, doxorubicin, and paclitaxel with lower mean chemosensitivity for carboplatin and paclitaxel.  Combination chemotherapy had higher chemosensitivity than single-drug chemotherapy.  However, in 25 % of patients a single-drug had higher chemosensitivity than combination chemotherapy.  As single agents, ifosfamide, cisplatin, and paclitaxel had the highest kinetic unit values.  The authors concluded that using a panel of agents simulating clinical dose regimens, the MiCK apoptosis assay was feasible in evaluating in-vitro chemosensitivity of endometrial cancer.  The MiCK apoptosis assay results correlated with GOG clinical trial results.  However, 25 % of patients might be best treated with single-agent chemotherapy selected by the MiCK assay.  Ifosfamide, cisplatin, and paclitaxel appear to have high activity as single agents.  The authors stated that the MiCK apoptosis assay may be useful in future new drug testing and individualizing endometrial cancer patient's chemotherapy management.

Bosserman et al (2012) noted that blinded clinical trials have shown higher response rates and longer survival in groups of patients with acute myelocytic leukemia (AML) and epithelial ovarian cancer who have been treated with drugs that show high apoptosis in the MiCK apoptosis assay.  Un-blinded clinical trials in multiple tumor types have shown that the assay will be used frequently by clinicians to determine treatment, and when used, results in higher response rates, longer times to relapse, and longer survivals.  Model economic analyses suggest possible cost savings in clinical use based on increased generic drug use and single-agent substitution for combination therapies; 2 initial studies with drugs in development are promising.  The authors concluded that the MiCK apoptosis assay may help reduce costs and speed time to drug approval; correlative studies with molecular biomarkers are planned.  They stated that this assay may have a role both in personalized clinical therapy and in more efficient drug development.

In a prospective, multi-institutional and blinded trial, Salom et al (2012) examined if the MiCK apoptosis assay could predict the best therapy for patients with ovarian cancer.  The MiCK assay was performed in 104 evaluable ovarian cancer patients treated with chemotherapy.  The assay was performed prior to therapy, but treating physicians were not told of the results and selected treatment only on clinical criteria.  Outcomes (response, time to relapse, and survival) were compared to the drug-induced apoptosis observed in the assay.  Overall survival in primary therapy, chemotherapy naïve patients with stage III or IV disease was longer if patients received a chemotherapy that was best in the MiCK assay, compared to shorter survival in patients who received a chemotherapy that was not the best (p < 0.01, hazard ratio HR 0.23).  Multi-variate model risk ratio showed use of the best chemotherapy in the MiCK assay was the strongest predictor of overall survival (p < 0.01) in stage III or IV patients.  Standard therapy with carboplatin plus paclitaxel (C + P) was not the best chemotherapy in the MiCK assay in 44 % of patients.  If patients received C + P and it was the best chemotherapy in the MiCK assay, they had longer survival than those patients receiving C + P when it was not the best chemotherapy in the assay (p = 0.03).  Relapse-free interval in primary therapy patients was longer if patients received the best chemotherapy from the MiCK assay (p = 0.03, HR 0.52).  Response rates (CR + PR) were higher if physicians used an active chemotherapy based on the MiCK assay (p = 0.03).  The authors concluded that the MiCK apoptosis assay can predict the chemotherapy associated with better outcomes in ovarian cancer patients.  They stated that this study quantified outcome benefits on which a prospective, randomized trial can be developed.

Strickland et al (2013) examined if the level of drug-induced apoptosis (chemosensitivity) demonstrated by the MiCK assay significantly predicted outcomes after standard AML induction therapy.  A total of 109 patients with untreated AML had blood and/or bone marrow aspirate samples analyzed for anthracycline-induced apoptosis using the MiCK assay.  The amount of apoptosis observed over 48 hrs was determined and expressed as KU of apoptosis.  Complete remission (CR) was significantly higher (72 %) in patients with high idarubicin-induced apoptosis greater than 3 KU compared to patients with apoptosis less than or equal to 3 KU (p = 0.01).  Multi-variate analysis showed the only significant variables to be idarubicin-induced apoptosis and karyotype.  Median overall survival of patients with idarubicin-induced apoptosis greater than 3 KU was 16.1 months compared to 4.5 months in patients with apoptosis less than or equal to 3 KU (p = 0.004).  Multi-variate analysis showed the only significant variable to be idarubicin-induced apoptosis.  The authors concluded that chemotherapy-induced apoptosis measured by the MiCK assay demonstrated significant correlation with outcomes and appeared predictive of complete remission and overall survival for patients receiving standard induction chemotherapy.

There is currently insufficient evidence that the use of the MiCK apoptosis assay improves survival of cancer patients.  Well-designed studies are needed to ascertain clinical value of the MiCK apoptosis assay.

Bellamy (1992) stated that cancer chemotherapy has witnessed a great deal of progress since the introduction of the nitrogen mustards in the 1940s.  Unfortunately, individual patients with apparently identical tumor histologies do not always respond identically to the same drug regimen.  Determining the sensitivity and resistance of an organism before treatment has been the standard of care in infectious diseases for many years, while in oncology treatment has been initiated according to tumor histology rather than the tumor's sensitivity to a given agent.  Attempts to individualize therapy have been the goal of oncologists since the 1950s.  Since that time a number of in-vitro assays have been developed to predict therapeutic outcome prior to the start of therapy.  In the 1970s, with the introduction of the human tumor stem cell assay, it was generally believed that oncology was on the threshold of entering an era of predictive in-vitro chemosensitivity testing.  Unfortunately, this assay was shown to have a number of technical drawbacks including the low plating efficiencies of many primary tumor samples, which thus limited the percentage that can be evaluated, leaving clinicians still at this threshold today.  Several recent developments, such as the Kern assay, which measures inhibition of radioactive precursors into tumor cells in the presence of antineoplastic agents, ATP bioluminescence assays, and the fluorescent Cytoprint assay offer the promise of rapid and sensitive results.  Other assays, such as the tetrazolium-based MTT and the sulphorhodamine blue assay appear to hold more promise in the screening and evaluation of potential new agents in established tumor cell lines than for evaluating chemosensitivity of clinical specimens.  However, before a particular assay can be considered as an in-vitro test of chemosensitivity or resistance, controlled prospective studies must be carried out to validate the assay in a number of different tumor types.

Tavassoli et al (1995) noted that in-vitro chemosensitivity assays (IVCAs) are expensive laboratory tests utilized to assist oncologists in the selection of chemotherapeutic regimens.  Their utility is disputed; yet, these assays continue to be requested because of the importance of the information they can provide and their scientifically logical approach.  Therefore, these researchers compared the results of 2 assays offered to clinicians at the authors’ hospital; the extreme drug resistance assay performed by Oncotech (OT) and the fluorescent Cytoprint assays performed by Analytical Biosystems (AB).  The 2 techniques used and the expression of assay results by the 2 companies were discussed.  A total of 20 neoplasms, all at least 3 cm in diameter and predominantly of breast and ovarian origin, were compared.  Oncotech performed 74 drug assays on 17 tumors, while AB performed 194 assays on the corresponding neoplasms; 3 neoplasms were insufficient for comparison.  Evaluation of the results revealed apparent disagreement on at least 44 drug assays with complete disagreement on at least 2 of the drugs tested in 12 of 17 cases.  The authors concluded that based on available information, comparisons between IVCAs showed great variation in results; moreover they stated that prospective studies are needed to evaluate commercially available assays for correlation with clinical outcome, and results should be expressed so comparisons can be readily made.

1. the FCA represents a feasible method for quickly assaying tumors for sensitivity to multiple chemotherapeutic agents; and
2. malignant gliomas may be particularly sensitive to 4-HC. 

The findings of this feasibility study need to be validated by well-designed studies.

In a prospective study, Rutherford et al (2013) evaluated the use of a chemoresponse assay in recurrent ovarian cancer patients.  Women with persistent or recurrent ovarian cancer were enrolled under an IRB-approved protocol, and fresh tissue samples were collected for chemoresponse testing.  Patients were treated with 1 of 15 protocol-designated treatments empirically selected by the oncologist, blinded to the assay results.  Each treatment was classified by the assay as:

1. sensitive (S),
2. intermediate (I), or
3. resistant (R). 

Patients were prospectively monitored for PFS and OS.  Associations of assay response for the physician-selected treatment with PFS and OS were analyzed.  A total of 262 evaluable patients were enrolled.  Patients treated with an assay-sensitive regimen demonstrated significantly improved PFS and OS while there was no difference in clinical outcomes between I and R groups.  Median PFS was 8.8 months for S versus 5.9 months for I+R (HR = 0.67, p = 0.009).  The association with assay response was consistent in both platinum-sensitive and platinum-resistant tumors (HR: 0.71 versus 0.66) and was independent of other covariates in multi-variate analysis (HR = 0.66, p = 0.020).  A statistically significant 14-month improvement in mean OS (37.5 months for S versus 23.9 months for I+R, HR = 0.61, p = 0.010) was demonstrated.  The authors concluded that this prospective study demonstrated improved PFS and OS for patients with either platinum-sensitive or platinum-resistant recurrent ovarian cancer treated with assay-sensitive agents.  Moreover, they stated that “ChemoFx, the chemoresponse assay employed in the current study, has been previously evaluated in retrospective studies inclusive of both primary and recurrent epithelial ovarian cancer (EOC).  These promising results warranted further evaluation in the form of this current prospective, multi-site, non-interventional trial …. Furthermore, the results suggest that effective (sensitive) treatment options could be available for many more patients than is currently achieved by empiric treatment.  These compelling data suggest that it may be reasonable to prospectively utilize chemoresponse assays to assist clinicians in the optimal prioritization of therapy for both platinum-sensitive and platinum-resistant patients with recurrent EOC”.

Grendys et al (2014) summarized recent scientific and medical literature regarding chemoresponse assays or chemotherapy sensitivity and resistance assays (CSRAs), specifically as applied to epithelial ovarian cancer.  A total of 67 articles, identified through PubMed using the key words "in vitro chemoresponse assay", "chemo sensitivity resistance assay", "ATP", "HDRA", "EDR", "MiCK", and "ChemoFx" were reviewed.  Recent publications on marker validation, including relevant clinical trial designs, were also included.  Recent CSRA research and clinical studies were outlined in this review.  Published findings demonstrated benefits regarding patient outcome with respect to recent CSRAs.  Specifically, analytical and clinical validations, as well as clinical utility and economic benefit, of the most common clinically used CSRA in the United States support its use to aid in making effective, individualized clinical treatment selections for patients with ovarian cancer.  Moreover, the authors stated that despite several years of chemoresponse assay development and clinical experience with these assays, studies have largely been confined to single-institutional, retrospective evaluations.  Recent large, prospective, multi-site clinical studies that correlate ChemoFx assay results with OS and PFS in both primary and recurrent ovarian cancers indicated that the assay may offer significant clinical benefit for patients, is predictive of treatment outcomes, and is potentially economically beneficial by reducing the chance that ineffective chemotherapy is administered.

1. sensitive,
2. intermediate sensitive (IS), or
3. resistant. 

Association of assay response with PFS was analyzed using the Kaplan-Meier method and a Cox regression model.  Patients whose tumors were resistant to carboplatin were at increased risk of disease progression compared to those with non-resistant (sensitive + IS) tumors (median PFS: 11.8 versus 16.6 months, respectively, p < 0.001), and the association was confirmed after adjusting for other clinical factors (HR, 1.71; 95 % CI: 1.12 to 2.62; p = .013).  Association of assay response to paclitaxel with PFS trended in multi-variate analysis (HR, 1.28; 95 % CI: 0.84 to 1.95; p = 0.245).  For tumors resistant to carboplatin, 59 % were sensitive or IS to at least 1 other commonly used agent, demonstrating the ability of the assay to inform treatment decisions beyond the standard platinum/taxane regimen.  The authors concluded that assay resistance to carboplatin is strongly associated with shortened PFS among advanced-stage epithelial ovarian cancer patients treated with carboplatin + paclitaxel therapy, supporting use of this assay to identify patients likely to experience early recurrence on standard platinum-based therapy.  They stated that the chemoresponse assay evaluated herein is independently associated with PFS and may be used to predict platinum resistance in patients with advanced-stage EOC prior to treatment.  Patients predicted for poorer outcome (i.e., platinum resistance) by the assay (and in conjunction with other clinical factors) may be considered for investigation of alternate treatment options.

Tian et al (2014) stated that recently, a prospective study (Rutherford et al, 2013) reported improved clinical outcomes for recurrent ovarian cancer patients treated with chemotherapies indicated to be sensitive by a chemoresponse assay (ChemoFx), compared with those patients treated with non-sensitive therapies, thereby demonstrating the assay's prognostic properties.  Due to cross-drug response over different treatments and possible association of in-vitro chemosensitivity of a tumor with its inherent biology, further analysis is required to ascertain whether the assay performs as a predictive marker as well.  Women with persistent or recurrent EOC (n = 262) were empirically treated with 1 of 15 therapies, blinded to assay results.  Each patient's tumor was assayed for responsiveness to the 15 therapies.  The assay's ability to predict PFS was assessed by comparing the association when the assayed therapy matches the administered therapy (match) with the association when the assayed therapy is randomly selected; not necessarily matching the administered therapy (mismatch).  Patients treated with assay-sensitive therapies had improved PFS versus patients treated with non-sensitive therapies, with the assay result for match significantly associated with PFS (HR = 0.67, 95 % CI: 0.50 to 0.91, p = 0.009).  On the basis of 3,000 simulations, the mean HR for mismatch was 0.81 (95 % range = 0.66 to 0.99), with 3.4 % of HRs less than 0.67, indicating that HR for match is lower than for mismatch.  While 47 % of tumors were non-sensitive to all assayed therapies and 9 % were sensitive to all, 44 % displayed heterogeneity in assay results.  Improved outcome was associated with the administration of an assay-sensitive therapy, regardless of homogeneous or heterogeneous assay responses across all of the assayed therapies.  The authors concluded that these analyses provided supportive evidence that this chemoresponse assay is a predictive marker, demonstrating its ability to discern specific therapies that are likely to be more effective among multiple alternatives.  They stated that clinical validations for chemoresponse assays, which simultaneously assess multiple markers/therapies, must be carefully considered.  Through further analysis of a prospective study and by using several analytical approaches, the current study further evaluated the clinical value of a chemoresponse assay.  The results provided reasonable evidence that this assay is a predictive marker, with the capacity to discern specific therapies that are likely to be more effective, and women with recurrent EOC may benefit from assay-informed therapy selection.

Moreover, the National Comprehensive Cancer Network’s clinical practice guideline on “Ovarian cancer” (Version 3.2014) states that “Chemotherapy/resistance assays and/or other biomarker assays are being used in some NCCN Member Institutions to aid in selecting chemotherapy in situations where there are multiple equivalent chemotherapy options available; however, the current level of evidence (category 3) is not sufficient to supplant stand-of-care chemotherapy.  Thus, the NCCN panel felt that in vitro chemosensitivity testing to choose a chemotherapy regimen for recurrent disease situations should not be recommended (category 3) owing to the lack of demonstrable efficacy for such an approach.  ASCO also does not recommend use of chemotherapy sensitivity and resistance assays, unless in a clinical trial setting”.

Tartar and colleagues (2016) stated that an alternative approach to the current therapy of ovarian carcinoma is the individualization of treatment by determining the sensitivity of tumoral tissue to chemotherapeutic agents before the initiation of chemotherapy.  These researchers examined the effectiveness of in-vitro chemosensitivity assays in ovarian carcinoma and measured the correlation of 3 leading assays.  Fresh tumoral tissue samples of 26 newly diagnosed primary ovarian cancer patients were studied with 3-(4,5-dimeth-ylthiazol-2-yl)-2,5-diphenyltetrazolyum bromide (MTT) assay, adenosine triphosphate-tumor chemosensitivity assay (ATP-TCA) and differential staining cytotoxicity (DISC) assays.  Chemosensitivity of tumors were studied for paclitaxel, carboplatin, docetaxel, topotecan, gemcitabine, and doxorubicin with each of the 3 assays.  Subgroup analysis was performed for stage, grade, and histologic type.  The in-vitro chemosensitivity results of MTT, ATP, and DISC assays were found to be similar.  The subgroups in which in-vitro assays would be more useful were encountered for patients with advanced stage and serous histology ovarian carcinoma.  The authors concluded that in-vitro chemosensitivity can be determined in ovarian carcinoma with ATP, MTT, or DISC assays before the initiation of chemotherapy; these 2 assays correlated well with each other and were particularly useful for serous and advanced cancers.  Moreover, these investigators stated that large prospective randomized studies comparing standard versus assay-directed therapy with an end-point of OS are needed before routine clinical utilization of these assays.

Kwon and associates (2016) evaluated the usefulness of the in-vitro ATP-based chemotherapy response assay (ATP-CRA) for prediction of clinical response to fluorouracil-based adjuvant chemotherapy in stage II CRC.  Tumor specimens of 86 patients with pathologically confirmed stage II colorectal adenocarcinoma were tested for chemosensitivity to fluorouracil.  Chemosensitivity was determined by cell death rate (CDR) of drug-exposed cells, calculated by comparing the intracellular ATP level with that of untreated controls.  Among the 86 enrolled patients who underwent radical surgery followed by fluorouracil-based adjuvant chemotherapy, recurrence was found in 11 patients (12.7 %).  The CDR of greater than or equal to 20 % group was associated with better disease-free survival (DFS) than the CDR of less than 20 % group (89.4 % versus 70.1 %, p = 0.027).  Multivariate analysis showed that CDR of less than 20 % and T4 stage were poor prognostic factors for DFS after fluorouracil-based adjuvant chemotherapy.  The authors concluded that in-vitro ATP-CRA may be a useful assay for identifying patients who might benefit from fluorouracil-based adjuvant chemotherapy in stage II CRC.  A major drawback of this study was the threshold value of 20 % CDR for defining chemotherapy-sensitive and -resistant groups.  Previous studies have reported various threshold values for CDR, ranging from 30 % to 50 %.  This discrepancy suggested the difficulty of the clinical application.  Thus, these findings should be confirmed in independent patient cohorts.

NexGen Cancer Cytotoxicity Assay

The NexGen Cancer Cytotoxicity Assay is a chemo-therapeutic drug toxicity assay of cancer stem cells that are cultured from primary tumor cells.  Categorical drug response to drug combinations is reported based on percent cytotoxicity that is observed.  There are a lack of published data on the effectiveness of this assay in improving clinical outcomes.

3D Predict Glioma / Reverse Phase Protein Array (RPPA)

Ex-vivo three-dimensional (3D) cell culture platforms use live cancer cells from surgical or biopsy specimens to create a patient-specific in-vivo like tumor that is used to predict response to approved and investigational cancer drugs.  This technique uses in-vitro assessment of drug-on-tumor cell interaction prior to in-vivo therapy administration.  Newer techniques include ex-vivo 3D cell culture platforms (Kiyatec, Inc.) and reverse phase protein array (RPPA) (Theralink Technologies).  The 3D Predict Glioma is an ex-vivo 3D cell culture assay that prospectively predict drug response for patients with glioma.   Reverse phase protein arrays (RPPA) are used to quantify proteins and protein post-translational modifications in cellular lysates and body fluids; RPPA measures the abundance and activation of cell surface receptor proteins and their down-stream signaling pathways.

Byron and co-workers (2020) stated that reverse-phase protein array (RPPA) technology uses panels of high-specificity antibodies to measure proteins and protein post-translational modifications in cells and tissues.  The approach offers sensitive and precise quantification of large numbers of samples and has found applications in the analysis of clinical and pre-clinical samples.  Leveraging a collaborative RPPA model, these researchers examined the variability between 3 different RPPA platforms using distinct instrument set-ups and workflows.  Using multiple RPPA-based approaches operated across distinct laboratories, they characterized a range of human breast cancer cells and their protein-level responses to 2 clinically relevant cancer drugs.  These investigators integrated multi-platform RPPA data and used un-supervised learning to identify protein expression and phosphorylation signatures that were not dependent on RPPA platform and analysis workflow.  These findings indicated that proteomic analyses of cancer cell lines using different RPPA platforms could identify concordant profiles of response to pharmacological inhibition, including when using different antibodies to measure the same target antigens.  These findings highlighted the robustness and the reproducibility of RPPA technology and its capacity to identify protein markers of disease or response to therapy.

These researchers stated that their data showed that RPPA analyses of drug-treated breast cancer cells using distinct antibodies and different RPPA platforms could identify robust profiles of protein markers reporting signaling pathway responses to pharmacological inhibition.  This suggested that the consistency of RPPA-based assays will enable the validation and assessment of treatment response and resistance mechanisms in clinical samples across international laboratories.  They noted that, to their best knowledge, these data provided the first extensive cross-platform validation of RPPA technology, which paves the way for further investigation and improvement of technology robustness.

Coarfa and associates (2021) noted that RPPA is a high-throughput antibody-based targeted proteomics platform that could quantify hundreds of proteins in thousands of samples derived from tissue or cell lysates, serum, plasma, or other body fluids.  Protein samples are robotically arrayed as micro-spots on nitrocellulose-coated glass slides.  Each slide is probed with a specific antibody that could detect levels of total protein expression or post-translational modifications, such as phosphorylation as a measure of protein activity.  These researchers described work-flow protocols and software tools that they had developed and optimized for RPPA in a core facility setting that included sample preparation, microarray mapping and printing of protein samples, antibody labeling, slide scanning, image analysis, data normalization and quality control, data reporting, statistical analysis, and management of data.  The authors’ RPPA platform currently analyzes approximately 240 validated antibodies that primarily detect proteins in signaling pathways and cellular processes that are important in cancer biology.  This is a robust technology that has proven to be of value for both validation and discovery proteomic research and integration with other omics data sets.

These investigators noted that as an example of the work-flow process applied to an experimental system, they employed RPPA to analyze the effects of steroid hormones in an estrogen receptor (ER)- and progesterone receptor (PR)-positive human ductal carcinoma in-situ (DCIS) cell line.  Human DCIS.com cells were engineered to express both ER and PR, and the cell line has been previously characterized as an in-vitro model of luminal DCIS that is highly responsive to both estrogen and progesterone.  ER and PR are ligand-dependent steroid receptor nuclear transcription factors that act primarily to regulate expression of gene networks.  They also mediate rapid effects of steroid hormones on extra-nuclear protein-signaling pathways via alteration of protein kinase activity and phosphorylation of protein substrates and down-stream events.  DCIS cells were treated with vehicle (ethanol) or E2 (1 nM E2) together with a progestin agonist (10 nM R5020 (17 alpha, 21-dimethyl-19-nor-pregna-4, 9-diene-3,20-dione)) for either 6 or 24 hours in triplicate experimental cultures.  Cell lysates were prepared and spotted on slides and processed for labeling with the authors’ validated antibody inventory using standard protocols and work-flow processes.  These researchers stated that RPPA, as deployed in their core, has proven to be a valuable discovery tool in cancer cell lines and animal models, especially to identify changes in phosphorylation of key regulatory proteins as markers of alterations in the activity-signaling pathways that contribute to cancer cell biology.  As with all omics platforms, RPPA in this context is a discovery and hypothesis-generating tool requiring further confirmation and guiding the prioritization of in-depth analysis of specific protein pathways.

Shuford and colleagues (2021) stated that clinical outcomes in high-grade glioma (HGG) have remained relatively unchanged over the past 30 years with only modest increases in OS.  Despite the validation of biomarkers to classify treatment response, most newly diagnosed (ND) patients receive the same treatment regimen.  These researchers examined if a prospective functional assay that provides a direct, live tumor cell-based drug response prediction specific for each patient could accurately predict clinical drug response prior to treatment.  A modified 3D cell culture assay was validated to establish baseline parameters including drug concentrations, timing, and reproducibility.  Live tumor tissue from HGG patients were tested in the assay to establish response parameters.  Clinical correlation was determined between prospective ex-vivo response and clinical response in ND HGG patients enrolled in 3D-PREDICT (ClinicalTrials.gov Identifier: NCT03561207).  Clinical case studies were examined for relapsed HGG patients enrolled on 3D-PREDICT, prospectively assayed for ex-vivo drug response, and monitored for follow-up.  Absent biomarker stratification, the test accurately predicted clinical response/non-response to temozolomide in 17/20 (85 %, p = 0.007) ND patients within 7 days of their surgery, prior to treatment initiation.  Test-predicted responders had a median OS post-surgery of 11.6 months compared to 5.9 months for test-predicted non-responders (p = 0.0376).  Case studies provided examples of the clinical utility of the assay predictions and their impact upon treatment decisions resulting in positive clinical outcomes.  The authors concluded that this study both validated the developed assay analytically and clinically and provided case studies of its implementation in clinical practice.

These researchers stated that in this study, multiple confounding factors unrelated to assay performance may have impacted outcomes, including time between resections and chemotherapy initiation, bevacizumab/chemotherapy combinations, radiographic versus clinical assessment to define progression, other treatments including carmustine wafers, tumor treating fields (TTF) therapy, and gamma knife radiosurgery, inclusion of anaplastic astrocytoma (AA), which in general has a higher survival rate than glioblastoma (GBM), and selection bias toward patients with good performance status for resection.  In the recurrent population, time between resection and treatment initiation averaged 6.7 weeks (3 to 14 weeks) with the longest being for the patients who received dabrafenib as time was spent waiting for insurance approval.  The 3D Predict Glioma assay currently does not evaluate bevacizumab response; thus, assay response to single agent was examined in relation to published PFS for patients clinically treated by a bevacizumab combination.  These investigators stated that future interventional studies will provide better control over other treatments; however, the inherent selection bias will always be present as fresh, live tissue is needed for assay performance.  Future development to reduce required tissue amounts for assay performance may increase the number of patients able utilize the assay.  Finally, the performance of a large RCT will provide better evidence of the assay’s usefulness.

Mariappan and colleagues (2021) noted that the human brain organoids derived from pluripotent cells are a new class of 3D tissue systems that recapitulates several neural epithelial aspects.  Brain organoids have already helped efficient modeling of crucial elements of brain development and disorders.  Brain organoids’ suitability in modeling glioma has started to emerge, offering another usefulness of brain organoids in disease modeling.  Although the current state-of-the organoids mostly reflect the immature state of the brain, with their vast cell diversity, human brain-like cytoarchitecture, feasibility in culturing, handling, imaging, and tractability could offer enormous potential in reflecting the glioma invasion, integration, and interaction with different neuronal cell types.  These researchers examined the current trend of employing brain organoids in glioma modeling and discussed the immediate challenges.  Solving them might lay a foundation for using brain organoids as a pre-clinical 3D substrate to dissect the glioma invasion mechanisms in detail.  The authors concluded that the recently emerged 3D human brain organoids have unexpectedly offered researchers studying glioma biology in a new dimension, offering an excellent opportunity to visualize glioma cancer stem cells (GSCs) invasion in human brain-like tissues.  With its neural stem cells, early and mature neurons, astrocytes, and microglial cells, brain organoids provide a suitable brain-like micro-environment for GSCs growth.  Human brain organoids did not exist in the past 10 years, and organoid-based GSCs invasion assays were not available just 3 years ago.  These investigators stated that it is an exciting era for glioma researchers as one could map GSCs invasion in ex-vivo.  However, there are significant bottlenecks, and addressing them will allow researchers to model the vicious cycle of GSCs, such as the aggressive behavior of GSCs along white matter paths of the human brain (like corona radiates), peri-vascular invasion/niching and escape from immunological surveillance.  From a clinical standpoint, optimizing the assays is crucial to identify responses on the sensitivity of a given tumor sample to irradiation or drug treatments within a few weeks of surgery.  Such early responses will aid in predicting patient survival after standard treatment and, hopefully, tailor personalized therapies.  These innovations await future experiments.

ERCC1 rs11615 Polymorphism and Chemosensitivity to Platinum Drugs in Ovarian Cancer

In a systematic review and meta-analysis, Zhang and colleagues (2021) examined the relationship between excision repair cross-complementary enzyme 1 (ERCC1) rs11615 polymorphism and chemosensitivity to platinum drugs in ovarian cancer.  PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), and China Wanfang databases were searched up to September 2020 to identify the relationship between ERCC1 rs11615 polymorphism and chemosensitivity of ovarian cancer.  Data were analyzed by Stata 15.0 statistic software.  A total of 10 published papers were included, including 1,866 patients with ovarian cancer.  The results showed that compared allele C at ERCC1 rs11615 locus with allele T, the pooled OR was 0.92 (95 %CI: 0.68 ~ 1.24, p > 0.05).  There were no significant differences in recessive, dominant, homozygous, and heterozygous models.  In accordance with a subgroup analysis of ethnicity, all genotypes were statistically significant in the Asian population.  In the allelic, dominant, recessive, homozygous and heterozygous models, the OR was 0.70 (95 % CI: 0.51 ~ 0.95), 0.20 (95 % CI: 0.07 ~ 0.56), 0.79 (95 % CI: 0.63 ~ 1.00), 0.21 (95 % CI: 0.07 ~ 0.59), 0.19 (95 % CI: 0.07 ~ 0.54), respectively, while in the Caucasian population, no statistically significant genotype was found.  The authors concluded that the ERCC1 rs11615 polymorphism is associated with chemosensitivity in patients with ovarian cancer, especially in the Asian population, but not in the Caucasian population.  It may be that there are differences between chemotherapy sensitivity and ovarian cancer patients of various ethnicity.  It has been reported that several differences exist in chemotherapy sensitivity to gynecological tumors in different races.  Furthermore, it was possible that the included studies were limited, resulting in no differences in the Caucasian population.  Moreover, these researchers stated that the conclusions of this study still need to be further validated by larger sample size and high-quality clinical research.

The authors stated that this study had several drawbacks.  First, the number of studies included was relatively small.  After ethnicity subgroup analysis, there were only 5 studies in the Asian population and the Caucasian population, respectively, which had a certain impact on the robustness of the conclusion.  Second, the sample size was relatively small, which was likely to affect the testing efficiency of statistics.  Third, there was a certain publication bias in allele model and recessive gene model.  Last but not least, in the sensitivity analysis of the Asian population, only the conclusion of the heterozygous genetic model was stable, while the conclusion of other genetic models was unstable to a certain degree.

ERCC1 Protein Expression and Platinum Chemosensitivity in Non-Small-Cell Lung Cancer

In a meta-analysis, Li and Cheng (2020) examined the relationship between the expression of nucleotide ERCC1 protein and platinum chemosensitivity in patients with advanced non-small-cell lung cancer (NSCLC).  These investigators searched literature on the expression of ERCC1 and platinum chemosensitivity in patients with advanced NSCLC, which was published from January 2009 to August 2019 on the databases such as China Journal Full-text Database (CJFD), China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP, PubMed, Embase, and others.  Stata 15.0 was used for statistical analysis, and ethnicity subgroup analysis was taken.  A total of 14 studies were included and 1,337 patients were involved, of which 697 were ERCC1-positive, with a positive rate of 53.5 %.  The combined OR was 0.53 (95 % CI: 0.30 ∼ 0.79; p < 0.01).  The results of ethnicity subgroup analysis showed that there was no significant difference, with OR of 0.50 (95 % CI: 0.31 ∼ 0.82; p = 0.001) in Asian population and OR of 0.56 (95 % CI: 0.30 ∼ 1.07) in Caucasian population.  The authors concluded that the sensitivity to platinum chemotherapy in patients with ERCC1 protein negative expression in the middle and late stages of NSCLC was better than that in patients with positive expression, especially in Asian population.  On the other hand, there was no correlation in Caucasian population.  These researchers stated that the state of ERCC1 may be a potential biomarker for predicting the effectiveness of platinum chemotherapy in NSCLC; however, considering the limitations of this study, well-designed studies (prospective trials with larger sample sizes) are needed to confirm these findings.

The authors stated that this study had several drawbacks.  First, the methods used in the included literature were basically immunohistochemical (IHC) staining.  When it was used to detect the expression of ERCC1, there were differences in the scoring criteria among the studies.  Second, the scope of the selected research was narrow, mostly in Asian countries, only 9 in Europe and America, but none in Africa and other countries.  Third, although IHC was used to detect the expression of ERCC1 in all of the studies, the manufacturer, dilution concentration, and judgment criteria of antibody were not completely consistent, which may have influenced the results of meta-analysis.  Fourth, the test of publication bias on the overall study and the population in Asian countries showed that there was still a partial publication bias; however, these results should be interpreted with caution, as the criteria for judging gene expression were inconsistent in the selected studies.  Sensitivity tests may also be necessary.

Chemosensitivity Assay-Guided Metronomic Chemotherapy

Isacoff et al (2022) stated that cytotoxic chemotherapy remains the mainstay of treatment for advanced PDAC.  Emerging studies support metronomic chemotherapy (MCT) as effective, challenging established paradigms of dosing and schedules.  The blood-based ChemoSensitivity Assay has been shown to predict response and survival in advanced PDAC patients treated with standard chemotherapy.  In a retrospective, single-center study, these researchers combined these concepts for a highly personalized treatment approach.  This trial entailed a pilot cohort (n = 50) as well as a validation cohort (n = 45).  The ChemoSensitivity Assay was carried out at baseline and during therapy; results were correlated to drugs administered and patient outcomes.  MCT was administered based on the assay results at the treating physician's discretion.  Patients in the pilot cohort experienced favorable survival compared with historical controls (mOS of 16.8 months).  Patients whose treatment closely matched the ChemoSensitivity Assay predictions experienced longer median time on lines of therapy (5.3 versus 3.3 months, p = 0.02) and showed a trend for longer mOS (20.9 versus 12.5 months, p = 0.055) compared with those not closely matched.  These findings were confirmed in the validation cohort.  Overall, patients treated with MCT closely matching Assay results experienced a remarkable mOS of 27.7 months.  The authors concluded that the ChemoSensitivity profiling-guided MCT is a promising approach for personalized therapy in advanced PDAC.

The authors stated that drawback of this trial included its retrospective nature and relatively small size.  In addition, all patients were treated at a single center, introducing the possibility of selection bias.  The exact drug combinations administered varied greatly from patient to patient and evolved over time as treating physicians became more familiar with the ChemoSensitivity Assay.  These researchers stated that formalizing drug combinations and optimizing drug selection and schedules responsive to the ChemoSensitivity Assay results are needed such that this approach could be widely generalized.  A larger, prospective, guided study is needed and currently in development to fully validate the ChemoSensitivity Assay-guided MCT approach described here.  Validation of the assay signature against existing gene-expression databases could be performed, and an ongoing trial is examining this cross-platform comparison prospectively.  Further pre-clinical studies to optimize and understand the biological mechanisms of this approach are also needed.

Circulating Tumor and Invasive Cell Expression Profiling for Pancreatic Cancer

Yu et al (2022) noted that pancreatic adenocarcinoma (PDAC) remains a refractory disease; however, modern cytotoxic chemotherapeutics could induce tumor regression and extend life.  A blood-based, pharmacogenomic, chemosensitivity assay using gene expression profiling (GEP) of circulating tumor and invasive cells (CTICs) to predict treatment response was previously developed.  The combination regimen of 5-fluorouracil (5FU), leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) and gemcitabine/nab-paclitaxel (G/nab-P) are established frontline approaches for treating advanced PDAC; however, there are no validated biomarkers for treatment selection.  A similar unmet need exists for choosing 2nd-line therapy.  The chemosensitivity assay was examined in metastatic PDAC patients presenting for frontline treatment.  A prospective study enrolled patients (n = 70) before receiving either FOLFIRINOX or G/nab-P at a 1:1 ratio; 6 ml of peripheral blood was collected at baseline and at time of disease progression.  CTICs were isolated, GEP was carried out, and the assay was used to predict effective and ineffective chemotherapeutic agents. Treating physicians were blinded to the assay prediction results.  Patients receiving an effective regimen as predicted by the chemosensitivity assay experienced significantly longer median PFS (mPFS; 7.8 months versus 4.2 months; HR, 0.35; p = 0.0002) and median OS (mOS; 21.0 months versus 9.7 months; HR, 0.40; p = 0.005), compared with an ineffective regimen.  Assay prediction for effective 2nd-line therapy was examined.  The entire study cohort experienced favorable outcomes compared with historical controls, 7.1-month mPFS and 12.3-month mOS.  The authors concluded that chemosensitivity assay profiling is a promising tool for guiding therapy in advanced PDAC.  Moreover, these researchers stated that further prospective validation is under way.

Cancer Stem Cell Chemotherapeutic Drug Cytotoxicity Assays

Ranjan et al (2020) stated that chemotherapy-resistant cancer stem cells (CSC) may result in tumor recurrence in glioblastoma (GBM).  The poor prognosis of this disease emphasizes the critical need for developing a treatment stratification system to improve outcomes via personalized medicine.  These investigators described a case-series study of 12 GBM and 2 progressive anaplastic glioma cases from a single center prospectively treated using a CSC chemotherapeutics assay (ChemoID) guided report.  All patients were eligible to receive a stereotactic biopsy and thus undergo ChemoID testing.  These researchers selected one of the most effective treatments based on the ChemoID assay report from a panel of FDA-approved chemotherapy as monotherapy or their combinations for these subjects.  Patients were evaluated by MRI scans and response was assessed according to RANO 1.1 criteria.  Of the 14 cases reviewed, the median age of this patient cohort was 49 years (range of 21 to 63).  These investigators observed 6 CR (43 %), 6 PR (43 %), and 2 progressive diseases (PD; 14 %).  Patients treated with ChemoID assay-directed therapy, in combination with other modality of treatment (RT, LITT), had a longer median OS of 13.3 months (5.4 to NA), compared to the historical median OS of 9.0 months (8.0 to 10.8 months) previously reported.  Notably, patients with recurrent GBM or progressive high-grade glioma treated with assay-guided therapy had a 57 % probability to survive at 12 months, compared to the 27 % historical probability of survival observed in previous studies.  The authors concluded that the findings of this study suggested that the ChemoID Assay has the potential to stratify individualized chemotherapy choices to improve recurrent and progressive high-grade glioma patient survival.  These researchers noted that “We are currently conducting a multi-institutional phase-III clinical trial (NCT03632135) to determine the clinical validity of the ChemoID assay as a predictor of clinical response in recurrent GBM”.

Ranjan et al (2023a) noted that therapy-resistant CSCs contribute to the poor clinical outcomes of patients with recurrent GBM (rGBM) who fail standard of care (SOC) therapy.  ChemoID is a clinically validated assay for identifying CSC-targeted cytotoxic therapies in solid tumors.  In a randomized clinical trial (NCT03632135), the ChemoID assay, a personalized approach for selecting the most effective treatment from FDA-approved chemotherapies, improved the survival of patients with rGBM (2016 WHO classification) over physician-chosen chemotherapy.  In the ChemoID assay-guided group, median survival was 12.5 months (95 % CI: 10.2 to 14.7) compared with 9 months (95 % CI: 4.2 to 13.8) in the physician-choice group (p = 0.010) as per interim effectiveness analysis.  The ChemoID assay-guided group exhibited a significantly lower risk of death (HR = 0.44; 95 % CI: 0.24 to 0.81; p = 0.008).  The authors concluded that findings of this study offered a promising way to provide more affordable treatment for patients with rGBM in lower socio-economic groups in the U.S. and around the world.  Moreover, these researchers stated that although this study provided good therapeutic options for patients with rGBM, some potential drawbacks should be noted.  For example, ChemoID is a functional assay limited by the availability of viable tumor tissue samples.  This study only included rGBM subjects who underwent surgical resection or biopsy.  Patients with inoperable tumors or who were in poor health were not subjects in this trial.  These investigators stated that future studies should incorporate patients with newly diagnosed methyl-guanine-methyl-transferase (MGMT) unmethylated GBM, who would benefit from assay-guided intervention.  Furthermore, further studies should examine the use of genomic assays with this functional assay in larger cohorts for guiding treatment.

Ranjan et al (2023b) presented a prospective cohort study of 40 real-world unmethylated MGMT-promoter GBM patients treated utilizing ChemoID.  Eligible patients who underwent surgical resection for recurrent GBM were included in the study.  Most effective chemotherapy treatments were chosen based on the ChemoID assay report from a panel of FDA-approved chemotherapies.  These researchers carried out a retrospective chart review to determine OS, PFS, and the healthcare costs.  The median age of this patient cohort was 53 years (range of 24 to 76).  Patients treated prospectively with high-response ChemoID-directed therapy, had a median OS of 22.4 months (range of 12.0 to 38.4) with a log-rank p = 0.011, compared to patients who could be treated with low-response drugs who had instead an OS of 12.5 months (range of 3.0 to 27.4 months).  Patients with recurrent poor-prognosis GBM treated with high-response therapy had a 63 % probability to survive at 12 months, compared to 27 % of patients who were treated with low-response CSC drugs.  These investigators also found that patients treated with high-response drugs on average had an incremental cost-effectiveness ratio (ICER) of $48,893 per life-year saved compared to $53,109 of patients who were treated with low-response CSC drugs.  The authors concluded that the findings of this study suggested that the ChemoID Assay ouldn be used to individualize chemotherapy choices to improve poor-prognosis recurrent GBM patient survival and to lower the healthcare cost that impacts these patients.

---

References